Table 3.
After Diagnosis, Effect of BCSI on Patient Survival: | |||||||||
---|---|---|---|---|---|---|---|---|---|
Row | Analysis Method | Instruments Specified | Number of Groups perInstrument | Instrument F-Statistic | 1 year | 2 years | 3 years | 4 years | |
1 | Unadjusted OLS | None | na | na | 0.01 | 0.02 | 0.04** | 0.06** | |
2 | Adjusted OLSa | None | na | na | −0.001 | −0.003 | −0.0001 | 0.007 | |
3 | Instrumental Variable Estimatesa | BCSI Rate | 2 | 8.57*** | −0.32 | −0.68 | −0.57 | −0.51 | |
4 | 4 | 5.19*** | −0.37** | 0.54** | −0.45 | −0.65* | |||
5 | 8 | 3.43*** | −0.33** | −0.50** | −0.46* | −0.52* | |||
6 | 12 | 3.00*** | −0.23** | 0.41** | −0.33 | −0.11 | |||
7 | Radiation Distance | 2 | 21.79*** | −0.21* | −0.12 | −0.33 | −0.23 | ||
8 | 4 | 7.52*** | −0.14 | −0.22 | −0.39 | −0.38 | |||
9 | 8 | 3.30*** | −0.14 | −0.19 | −0.35 | −0.28 | |||
10 | 12 | 2.94*** | −0.05 | −0.14 | −0.33 | −0.40* | |||
11 | BCSI Rate and Radiation Distance | 2 | 13.08*** | −0.24** | −0.25 | −0.38* | −0.30 | ||
12 | 4 | 4.99*** | −0.24** | −0.32* | −0.39* | −0.45* | |||
13 | 8 | 2.76*** | −0.24** | −0.31** | −0.34* | −0.27 | |||
14 | 12 | 2.74*** | −0.12* | −0.23** | −0.30** | −0.15 |
Statistically significant at .99 confidence.
Statistically significant at .95 confidence.
Statistically significant at .90 confidence.
Models also specified binary variables for age groups (<50, 50–64, 65–69, 70–74, 75–79, 80–84, 85+), tumor sizes (<2 cm, 2–5 cm, 5+cm), positive lymph node involvement, tumor grade groups (1, 2, 3, 4, 9–unknown), tumor location groups (nipple, central portion, upper-inner quad, lower-inner quad, upper-outer quad, lower-outer quad, axillary tail, overlapping lesion, not stated), Charlson comorbidity index (0, 1, 2, 3+), residence zip code poverty percentage (#7, 7–10, 10–13, 13– 20, >20), distance from residence to nearest hospital (#2.83, 2.83–9, 9–15,>15), payer (Medicaid, Medicare, Blue Cross/Blue Shield, other private, other government, self-pay), and year of diagnosis (1989, 1990, 1991, 1992, 1993, 1994).